Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025
Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported a striking 9‑year overall survival with a complete response in an advanced liver cancer patient treated with its investigational drug Namodenoson, and confirmed that a pivotal Phase III trial in hepatocellular carcinoma (HCC) is now enrolling patients in multiple regions. GlobeNewswire+1 According to real‑time market data, Can-Fite’s American Depositary Receipts (ADRs) traded around $0.47 on November 18, up more than